DIABETEX INTERNATIONAL CORP
8-K, 2000-04-14
MEDICAL LABORATORIES
Previous: ECHAPMAN COM INC, SB-2/A, 2000-04-14
Next: MERCURY QA STRATEGY SERIES INC/, N-1A/A, 2000-04-14





- ----------------------------------------------------------------------------
Potential Persons who are able to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
- -----------------------------------------------------------------------------
                                                    -----------------------
                                                     OMB APRROVAL
                                                    ------------------------
                                                     OMB Number 3232-0060
                                                    ------------------------
                                                     Expires: May 31, 2000
                                                    ------------------------
                                                     Estimated average
                                                     burden hours
                                                     per response: 5
                                                    ------------------------

                         UNITED STATES
                    SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C. 20549

                        FORM 8-K
   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest reported):  April 14, 2000

                   Diabetex International, Corp.
        ------------------------------------------------------------
               (Exact Name of Registrant)
    Nevada                           000-30380        87-0458228
- ----------------------------- ------------------   -----------------------
(State or other jurisdiction    (Commission            (IRS Employer
   of incorporation)             File Number)            Identification No.)

7321 Roseville Road,Sacramento, CA             95482
- -------------------------------------    ------------------------
(Address of principal executive office)       (Zip Code)

Registrant's Telephone number, including area code  (702) 293-0909
                                                   --------------------------

            --------------------------------------------------------------
             (Former name or former address, if changed since last report)

ITEM 1.   CHANGES IN CONTROL OF REGISTRANT

There are no changes in the control of the Registrant.

ITEM 2.  ACQUISITION OR DISPOSITION OF ASSETS

There have been no acquisitons or dispositon of assets.

ITEM 3.  BANKRUPTCY OR RECERVSHIP

The Company is not in bankruptcy or recervship.

ITEM 4.  CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

The Company has not changed its Certifying Accountant.

ITEM 5.  RESIGNATIONS OF REGISTRANT'S DIRECTORS

While none of the Directors of the Company have resigned or failed to stand
for reelection the following changes to the Board of Directors is reported
herein:
           In addition to Philip Bloomquist as Director, Benjamin Brucker
Weisman, Ph.D is added to the Board.
           Mr. Bloomquist continues as the Chairman of the Board and Dr.
Weisman will assume the duties of a director and Chief Executive Officer.

ITEM 6.  FINANCIAL STATEMENTS AND EXHIBITS

No financial statements are included with this report.

Included as an Exhibit is a copy of the employment contract by and between Dr.
Weisman.

ITEM 7.  CHANGES IN FISCAL YEAR

There has been no change to the Company's fiscal year.

                                        Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                           Diabetex International, Corp.
                                        ----------------------------------

Date: April 14, 2000                   /s/ Philip Bloomquist
                                       ------------------------------------
                                           Philip Bloomquist
                                           Secretary




                                 EMPLOYMENT AGREEMENT

Diabetex International, Corp. (DI), the employer and Benjamin B. Weisman
(BBW), the employee enter into this contract for a twelve month period
commencing on the signing by both parties.

BBW will assume the position of chief executive officer (CEO of DI) and be
solely responsible for performing or delegating the following:

   1.  Hiring, dismissing and establishing the compensation package of all
       employees, consultants and independent contractors.  Legal counsel
       and accounting firms may be changed by the Board of Directors or
       shareholders at the recommendation of the CEO.

   2.  Establishing and supervising all strategic long term planning and
       budget preparation.

   3.  Recommending and reviewing numbers to both the Board of Directors and
       the advisory board.

   4.  To be the sole signatory of any corporate accounts.

   5.  To approve any contract which might affect the operations of DI.

   6.  To interact with the "Investment Community".

   7.  Perform those functions necessary to properly supervise and
       administer the operations of the business, including the
       miniturization and testing of non-invasive devices as the primary
       focus , along with marketing and establishing a business model for the
       metabolic activation clinics and commercializing the Hamilton-May pump.

In additon, BBW will become a member of the Board of Directors.

BBW will receive compensation of $60,000 and 132,000 shares of DI stock.  The
stock may be granted through stock option or given directly to BBW or is
disignate.  The determination as to the amount of payment and its form (notes
or cash) for the options, or the exercise thereof, within the terms of the
options will be made by BBW.  The company's securities counsel along with
Board will review and alter, with consent of BBW, any terms deemed to be
violative applicable rules and regulations. [All shares bear (sic)
"piggy back" registration rigts. /s/PRB /s/ BBW]

BBW will, at his option assume the position of chairman of the board within a
six month period from signing this contract.  Additional time and
responsibilities as chairman will be required.  For this BBW will receive a
50% increase in his compensation as CEO from the time he assumes the
chairmanship.

DI warrants that it has a minimum and $350,000 in cash and no liability or
contingent liabilities exist that would reduce the $350,000 cash position
except for the current day to day operational expenses included on an ongoing
basis.

Directors and Officers liability insurance that is approved by BBW will be
obtained by DI and maintained during the term of this agreement.

Di will defend BBW from any claim arising from execution of his duties
hereunder.  DI will pay any related costs not covered by insurance.

If for any reason other than malfeasant (sic) or criminal action, the contract
is terminated such as mergers or corporate combinations resulting in the
alteration of this contract BBW is to receive in full 12 months compensation
as stated in this contract.

Any disputes arising form this contract will be submitted to the New York
State Arbitration Board and their decision will be binding on both parties.


/s/ Benjamin B. Weisman                      04/14/00
- -------------------------------      --------------------------
Benjamin B Weisman                    Date:

/s/ Philip R. Bloomquist                     04/14/00
- -------------------------------       --------------------------
Diabetex International, Corp.
Philip R. Bloomquist
Board Chairman



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission